Marc Beer is one of the better executives in healthcare. Recently, he has been appointed by LumeNXT Inc as the chairman of the board. The company specializes in development of surgical illumination for minimal invasive surgeries. With more than two decades as an executive in different capacities, Mark knows what it takes to get the job done. He also understands the value of good healthcare and how to make the lives of people easier. Target illumination is really great for surgeons because they need to be accurate in everything they do concerning the human body. As a surgeon, target illumination makes everything easier because it allows flexibility, increases visualisation and more. This is not his first rodeo, he has guided companies Like ViaCell, Renovia and multiple other startups to a successful state. As a result of his previous successes, there was no question how much value he could add to LumeNXT. Before Renovia and LumeNXT, he was the chair executive of Minerva, a company specialized in curing central nervous diseases. In other capacities, he’s also been the chairman of the board of directors of compensation committees and a member of the board of tertiary institutions in Florida. As an entrepreneur different things excite him, one of which is the disruptive nature of unconventional startups. According to him startups like Tesla and Airbnb have made waves in respective industries forming a new way of thinking and pushing the boundaries of what is considered normal. As a result their own conforming nature makes them stand out and thrive in profit at an impeccable level. That’s one thing he’s trying to achieve at LumeNXT and Renovia. He highlights that to get the best results you need the best people and as a CEO, he prides himself on taking time to recruit those individuals that can meet his short-term and long-term goals. His strive for success is unparalleled and he brings ideas to life by crossing his T’s and dotting his I’s. When bringing an idea to life, he makes sure that he understands the legal, financial and commercial implications of the product. In future, hopes the role of digital healthcare becomes the norm and surpasses conventional healthcare. It might take a decade or two for this changes to happen, but he notes that it will be remarkable for saving lives and increasing profits of his company. To increase efficiency, he makes sure that resource allocation is perfect and there is no wastage. This allows every department get sufficient resources to foster the development of a product. As a result it promotes efficiency and effectiveness. Learn more: https://renoviainc.com/
Marc Beer Renovia is among the owners of the Renovia Inc. which is an upcoming venture. It focuses on producing fresh commodities for pelvic floor disorders. This is after a 42 million agreement was concluded with a medical firm. The company is located in Boston and is producing diagnostic drugs to treat the disorder such as urinary incontinence. The initial product Renovia created, Leva, was approved by the FDA. Longwood Fund is an institution that concentrates on healthcare and it invested in Renovia from the start. The funds obtained from the company are used to improve therapeutic goods such as modernized Leva machine. He undertook his studies from Miami University where he graduated with a BS.
Besides being in the health sector, Marc Beer Renovia is a strategic consultant to OvaScience. The biotech firm is based in Waltham where it announced that it is partnering with Millendo Therapeutics to improve their products. He has over 25 years of experience in biotechnology and diagnostics. Moreover, he has a wide knowledge of pharmaceuticals which makes him a competent health expert. Renovia was established in 2016 and closed financing with prominent capital funds. This was in the best interest of every individual of the company so as to develop it.
Marc Beer Renovia came up with ViaCell in 2000 making him the ultimate owner. It is a biotechnology firm which focuses on the collection of umbilical cord blood stem cells. He managed the company for seven years, which made it prosper in the commercial sector. Under his management, the firm developed to contain over 300 workers. While managing the company, he had several tasks with Genzyme. Lately, he served as the vice president of Global Marketing in which he had a duty of launching multiple commodities. The products being presented were of rare illnesses on a worldwide measure. Learn more: https://www.bizjournals.com/boston/news/2018/08/21/ex-aegerion-chief-beer-raises-42m-for-womens.html
Marc Beer is a graduate from Miami University where he earned a BS; upon graduation he devoted himself to work in various fields including pharmaceuticals, biotech technology, diagnostics, devices among others. Marc Beer is the founding chairman of the board of directors at the Compensation Committee for the Good Start Genetics company, and NASDAQ: NERV. He has also enrolled at the Miami University Business advisory council to share his insight on various businesses related to the health sector, and even the Notre Dame Research advisory committee. While working at Genzyme, Marc Beer served multiple roles regarding sales and marketing of the company’s products as well as managing the Abbott Laboratories.
Later Marc Beer joined the ViaCell company to serve as the CEO; the company specialized in collecting, preserving and developing various umbilical cord blood stem cells. Marc Beer served for almost seven years, and at the end of his reign the company had employed more than 300 employees to manage its operations; he ensured ViaCell traded publicly in 2005. Later Marc Beer in partnership with MD, Yolanda Loire and Ramon Iglesias founded Renovia company with the aim of establishing various series of healthcare venture capital funds. Renovia company found Leva Product which is a significant treatment for the Pelvic muscles strengthening and rehabilitating. Marc Beer has overseen completion of Series A project that did very well in the healthcare venture capital fund.
Recently Marc Beer introduced Series B project by raising $42 million to construct Boston-based healthcare center for women. They have employed a group of experts to research and establish new therapeutic and diagnostic treatments which are made with modern technology. Marc Beer has targeted more than 250 million women across the globe who suffer from Pelvic disorders precisely Urinary incontinence. Renovia company has advanced technologies which serve several purposes; Marc Beer has stated their partnership with Longwood company to share this technology as well as the skills to support the Series B foundation.
By the end of Series B, Marc Beer aims to have developed a digital program through which patients can access treatments guidelines and awareness about various diseases. This program will also provide knowledge and skills on treatments for pelvic disorders. Marc Beer understands that many women suffering from pelvic disorders fail to seek medical support since its very expensive he has therefore ensured that long-term healthcare services offered at Renovia re relatively low and affordable even to the middle-class income people. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer
In addition to the new Series B foundation, Marc Beer has announced the appointing of John A. Fallon a medical director to the company’s board of directors. He has also contributed to the establishment of REDUCE center to study and come up with the next generation treatment methods.
Nitin Khanna was born in Ambala, India and led a strict life as a Colonel’s son. While in India, he attended The Lawrence School and Purdue where he earned his Bachelor’s and Master’s degrees in industrial engineering.
Due to his desire for success as an ambitious entrepreneur, Nitin Khanna moved to Portland, Oregon and started his own company in 2009 named MergerTech. Merger Tech is a bank where Nitin Khanna provides personal and comprehensive advice to other companies on acquisitions and mergers.
Nitin Khanna’s expertise on mergers and acquisitions lead to much higher selling prices than normal for his clients in the sales of Mutual Mobile, Simple and many others. These sales earned Nitin Khanna the #1 spot in mobile banking, ahead of other prestigious banks like the Bank of America as detailed here.
One of his second biggest accomplishments was Nitin Khanna’s key role in the growth of Saber, a company he co-founded in 1998. By 2007, Saber Corp had grown by $120 million and had over 1200 employees. It sold to EDS for $460 million in 2007.
After the sale of Saber Corp, Nitin Khanna took over the business operations at EDS that included Saber. When he left there, EDS had over 1500 employees and $300 million in revenue.
Aside from his business ventures, this highly regarded entrepreneur, Nitin Khanna, has donated to charities like medical foundations for leukemia, Children’s Museum and The Urban League. His contributions earned him the award of Portland’s Top 40 in 2002 by Governor John Kitzhaber. Because of his many accomplishments, Nitin Khanna is still highly regarded by all other entrepreneurs in Portland, Oregon today.
He has operated as the Vice President of Global Marketing at Genzyme Therapeutics Worldwide. He was the President of Global Marketing at Sanofi Company between 1996 and 2000. Marc is also remembered at Biostar where he worked as the vice president of sales and marketing. He was employed as the chief executive officer at Viacell and was responsible for all aspects of the company’s development. Marc has worked for many years over 25 years commercializing and developing the biotechnology and pharmaceutical industry.
Marc Beer is not a health professional, but his impact on the healthcare industry is significant. He tries his best in helping women in the society who suffer from pelvic disorders such as urinary incontinence. He has made a considerable achievement in boosting the health of women. After working for 25 years in investment companies, Marc launched his company known as Renovia Inc. The company specializes in manufacturing health products which are used in diagnosis and management pelvic disorders.
Last Year, Marc Beer raised a lot of money more than $ 42 billion which was meant to fund a project his company. Many reputable investors and investment companies raised the fund. The project aimed at introducing a new array of medical products which will be used in the management of pelvic conditions. The fundraising was meant to help women in Boston and the world at large who are suffering from these conditions.
The healthcare industry is diverse. There are always different forms of treatment for various ailments. In this context, you will get to know more about the biotechnology industry and the leading companies in this sector. To be precise, Renovia Inc. will serve as our company of interest. Renovia Inc. is led by Marc Beer. The company was launched in 2016 with Marc Beer as the founder. As a biotechnology company, Renovia Inc. has been striving to find the most suitable forms of treatment for the pelvic floor disorders which are affecting women. Urinary continence is the most common pelvic floor disorder. Luckily, Renovia Inc. has been able to formulate various forms of treatment that have been meant to treat this ailment.
About Marc Beer and the $42M Fundraiser
Since 2016, Renovia Inc. has had some breakthroughs regarding the treatment options for the pelvic floor disorder. The main advantage that the company has hand revolves around the experience that Marc Beer has in the pharmaceutical and biotechnology industries. Additionally, Marc Beer is knowledgeable about the FDA approval process. Since Renovia Inc. was able to come up with Leva, their technology was able to pass the FDA approval process thanks to the knowledge that Marc Beer harbors in such areas. Although that was a significant achievement, Renovia Inc. needed more funds that would be used to ensure that the company can continue performing biotechnology-related research while in pursuit of a solution to the various ailments affecting people globally.
Since more than 250 million women are suffering from urinary continence and other pelvic floor disorders globally, Renovia Inc. is striving to ensure that they can also formulate more affordable forms of treatment. Urinary continence is a disorder, and it can only be managed; that is why Renovia Inc. is trying to come up with types of therapy that can be used to enhance the strength of the muscles within the body. If you are suffering from the pelvic floor disorder, you can utilize the Leva technology that was created by Renovia Inc. This form of technology can help you through your coaching sessions. It also offers visualizations in real time, and this is all possible courtesy of the Bluetooth device installed within the system.
Since Renovia Inc. is trying to come up with more advanced forms of the Leva technology, the biotechnology company had to seek finances through a fundraiser. Furthermore, the amount needed was $42M. Marc Beer was up to the task, and he ensured that everything has gone as planned. Although $10M was raised through venture debt, the Series B Funding had already accumulated a total of $32.3M. Renovia Inc. is now in a better position to come up with state-of-the-art diagnostic tools that will be used during the treatment of women with the pelvic floor disorders. Apart from that, Renovia Inc. will strive to come up with treatment techniques that are more affordable. Learn more: https://renoviainc.com/leadership/
Renovia Inc., a healthcare based investment firm has only been in operation for two years as it was established on August 2016. Nevertheless, in its two years of existence, the firm has marked milestones that companies which have been in play longer than that, aren’t even close to accomplishing. Its success can be attributed to its great leaders, led by Marc Beer.
Profitable investments that impact the lives of others positively
Having been in the healthcare sector all his life, Marc Beer boasts vast experience in the field of biotechnology, pharmaceuticals and several other areas of MedTech. This has helped him identify some of the most profitable areas to venture in, and this when combined by the many networking connections he boasts, has enabled him turn many of Renovia’s goals into a reality. It’s also essential to note that these investments benefit not only him, but impact the rest of the world positively as well.
For instance, under his direction, and that of the other two founding members of Renovia Inc., namely; Yolanda Lorie and Ramon Iglesias, Renovia Inc developed the first pelvic training device known as Leva. The primary objective for the development of the leva device is to improve the lives of more than 250 million women who suffer from pelvic disorders such as urinary incontinence after childbirth.
Marc Beer does it again
Marc Beer has once again brought triumph to Renovia Inc. after he led the company to secure a whopping $42.3 million, during its series B round founding. Again he achieved this through his top-shelf networking abilities. Once again the funding was inclusive of A-list healthcare investment firms such as Longwood, Ascension ventures, New York perceptive advisors and many others.
The primary purpose of the funding is to facilitate the development of a new generation Leva device which will further curb the prevalence of pelvic disorders. The funds will also be channeled to the development of three more diagnostic and therapeutic products which again, will help shape the health industry.
More insight into Marc Beer
Marc Beer has been at the helm of medical technology for more than two years now. His innovative skills when it comes to ground-breaking biotech and pharmaceutical developments has seen him be part of multiple MedTech giants. For instance, in his over 25 years career, Marc has served as Vice president of Genzyme’s global marketing team, where he helped facilitate the launch of products that address rare diseases. He was also an executive member of Erytech Pharma’s board of directors and also worked at Abbot Pharmaceuticals.
Marc Beer’s career path shows his outstanding leadership skill and commitment in the pharmaceutical field. Early 2000, he was appointed as the founding chief executive officer of ViaCell. The biotechnology company grew tremendously under his leadership managing to employ over three hundred workers. ViaCell Company mainly specializes in collecting umbilical cord blood stem cell, preserving and developing. After working for five years, Marc managed to move ViaCell Company publicly by 2005; two years later it was acquired by PerkinElmer.
Erytech Pharma appointed Mark as one of the boards of director members while working at ViaCell. Before he had joined ViaCell, he previously worked for the Genzyme. He used his expertise in sells and marketing in launching the company products. He has also served for many companies as founding chairman including Good Start Genetics, Minerva Neuroscience and as the advisory council of Miami University. Marc Beer is a graduate of Miami University with a bachelor of science degree.
His vast experience and expertise in pharmaceutical, biotechnology, innovation, and disease diagnosis were motivating factors to partner with Dr. Pulliam, Roman Iglesias, and Yolanda Lorie and started their company, Renovia. Mark shows the compassion in his duty by raising $42 million for finding the solution with regards to women health. He uses his innovation to find a product that will cure pelvic floor disorders.
The Pelvic floor disorders are as the result of the injury or weakening of the ligament, tissue and pelvic muscle. The condition is caused by the prolapse of the bladder, the urethra, rectum, and small intestine. Renovia Medtech Company is fully committed in research and find a product to diagnose the disorders. They estimate to reach around 250 million women across the globe. The company is looking for an exclusive way to train patient and strengthen the weak pelvic floors muscle while the patient is alone at home by investing in leva pelvic digital health system. Leva is their first product, and by April FDA approved it.
Leva product is visualized with technology that trains the patient to control urination. It has motion sensor technology that shows a vaginal profile of a woman when at rest or during movement, it is programmed to measure the time one requires during training, and it is easy for a patient to track and do a subsequent reading and share data using this technology. With the leva treatment, one requires no surgeries.
The funding from the Long wood is going to be used in developing of four products. Mark during an interview noted that the Renovia Company is appreciating the investors who willing are offering support to Boston based Medtech and it is so committed to provide treatment and change millions of lives of pelvic floor disorders patient in the world. Learn more: https://www.linkedin.com/in/marcbeer
Renovia Inc. is a startup organization that was founded by Marc Beer. Renovia is an organization in the pharmaceutical industry. The company will be moving forward with its new products that deal with pelvic floor disorders after it closed at $32 million Series B round. In addition to this, the company closed with another ten million in business debt. Renovia is located in Boston, and the company is coming up with several diagnostic and therapeutic products meant to cure pelvic floor disorders such as urinary incontinence. According to researchers, the disorder is affecting more than 250 million women around the globe. The first product of Renovia received approval from FDA in April. Longwood fund also joined Series B round too. Learn more: https://renoviainc.com/leadership/
Longwood is an organization that invests in companies that are dealing with healthcare. The organization is under Perspective Advisor in New York as well as Ascension Ventures base in Missouri. The funding will be used to create and testing four other diagnostic and therapeutic products including Leva device’s new generation. Marc Beer claimed that they were happy to have such partners who are ready to fund the shared vision to diagnose correctly, as well as treat, and enhance the lives of millions of women across the world who are suffering from pelvic floor disorders. By bringing together the company’s proprietary and innovative sensor technologies, the organization will be able to create elements with a digital health platform that will provide its clients with information about the company’s new treatment options.
In addition to this, the platform will allow the clients to get a better understanding of the disorders of the pelvic floor. Moreover, it will help the customers to be able to lower the costs of long-term health care. Renovia forms the first organization that Marc Beer has come up with since he left Aegerion. Marc has brought great talent to the organization since it was started in 2016. He believes that with this great team, the organization will soar high in terms of success in the coming years.
Marc takes his time to recruit the best of the best into his organization, a fact that gives him confidence that they will reach their goals. He believes that Renovia is the leader when it comes to the healthcare of women as well as in the digital health. Marc acknowledges the fact that there were earlier breakthroughs in peripheral vascular disease, pain management, and cardiac disorders. But there had never been such a breakthrough in women healthcare and digital healthcare until Renovia came into existence. Marc goes ahead to say that he knows that there will be more breakthroughs in the area in the future. According to Marc, all organizations require capital efficiency and resource allocation, and this is what has seen Renovia to its current state. Follow Marc Beer on LinkedIn
Pelvic floor dysfunction refers to the inability to tighten the pelvic floor muscles when having a bowel movement. The symptoms include urine leakage and constipation to mention a few. Treatments include biofeedback, surgery, and medication. Biofeedback allows the therapist to evaluate how the patient relaxes their pelvic muscles via special sensors after which the therapist will observe your coordination. Surgery is useful in loosening your affected pelvic floor organs if it’s rooted in rectal prolapse, a disorder that causes the rectal tissue to fall in your anal opening. In medication, your doctor will prescribe a muscle relaxer to prevent your muscles from contracting. But, most individuals suffering from pelvic floor disorders cannot access these treatment methods. Therefore, scientists, entrepreneurs, and donors have collaborated to finance the treatment. One such individual is Marc Beer. Learn more: https://www.slideshare.net/MarcBeer
Marc Beer’s Contribution
Marc Beer is the CEO of Renovia Inc. He is a talented entrepreneur with a problem-solving acumen for business. He has been transforming businesses into strong financial vehicles through strategic policies. The recent funding of $42 million for a biotechnology start-up Marc Beer co-founded has spoken about his reputation for transforming small businesses to successful companies with a reputable future. The collected funds will be used to finance the research and drug development of pelvic floor disorders since it’s an international healthcare problem that affects millions of women.
The Fund Raiser
The funds were raised by an infusion strategy that saw the start-up receive donations from various investment companies including Ascension Ventures and Longwood Fund. This donation will be used to improve the development of Revia, a fully FDA approved drug used to treat pelvic floor disorders. Marc Beer hopes that the new round of Series B Funding will catapult the company towards perfecting the diagnosis systems for pelvic floor disorders by partnering with revolutionary patient-based technologies that have valuable data. He also hopes that it will contribute to a reduced overhead cost for treating urinary incontinence.
Marc Beer is a business generator, motivational speaker and the co-founder of Renovia. He combines dynamism with charisma to generate a force to improve businesses. He marshals his resources to develop startups into useful businesses. He consistently looks out for challenges to find viable solutions and opportunities for the less fortunate. Over the years, he’s garnered experience from various companies including ViaCell where he was the CEO. In his tenure, the company succeeded in stem cell research thereby earning a stellar reputation in NASQAD. The employee base grew tremendously.
Beer is a business developer with extensive experience in sales, marketing, and pharmacy. Prior to joining the startup origination industry, he was the vice president of Genzyme, an international marketing company. He has a degree in science from Miami University.